188 related articles for article (PubMed ID: 28103324)
1. Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease.
Pello Lázaro AM; Cristóbal C; Franco-Peláez JA; Tarín N; Aceña Á; Carda R; Huelmos A; Martín-Mariscal ML; Fuentes-Antras J; Martínez-Millá J; Alonso J; Lorenzo Ó; Egido J; López-Bescós L; Tuñón J
PLoS One; 2017; 12(1):e0169826. PubMed ID: 28103324
[TBL] [Abstract][Full Text] [Related]
2. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events.
Fortuna LA; Pawloski PA; Parker ED; Trower NK; Kottke TE
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):13-9. PubMed ID: 27533057
[TBL] [Abstract][Full Text] [Related]
5. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
[TBL] [Abstract][Full Text] [Related]
6. Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes.
Geng T; Chen JX; Zhou YF; Lu Q; Wan Z; Liu L; Pan A; Liu G
J Clin Endocrinol Metab; 2023 May; 108(6):e216-e222. PubMed ID: 36573284
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome.
Rassen JA; Choudhry NK; Avorn J; Schneeweiss S
Circulation; 2009 Dec; 120(23):2322-9. PubMed ID: 19933932
[TBL] [Abstract][Full Text] [Related]
8. Intermittent concurrent use of clopidogrel and proton pump inhibitors did not increase risk of adverse clinical outcomes in Chinese patients with coronary artery disease.
He W; Shu X; Zhu E; Deng B; Lin Y; Wu X; Zhou Z; Wang J; Nie R
BMC Cardiovasc Disord; 2021 Feb; 21(1):75. PubMed ID: 33546595
[TBL] [Abstract][Full Text] [Related]
9. Sun exposure influences the prognostic power of components of mineral metabolism in patients with coronary artery disease.
Aceña A; Franco-Peláez JA; Gutierrez-Landaluce C; Pello AM; Cristóbal C; Tarín N; Huelmos A; Carda R; Martín-Mariscal ML; Alonso J; González-Parra E; González-Casaus ML; Lorenzo Ó; López Bescos L; Egido J; Tuñón J
Nutr Metab Cardiovasc Dis; 2017 Sep; 27(9):762-767. PubMed ID: 28803689
[TBL] [Abstract][Full Text] [Related]
10. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L;
Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200
[TBL] [Abstract][Full Text] [Related]
11. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
12. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention.
Sloth AD; Schmidt MR; Munk K; Kharbanda RK; Redington AN; Schmidt M; Pedersen L; Sørensen HT; Bøtker HE;
Eur Heart J; 2014 Jan; 35(3):168-75. PubMed ID: 24031025
[TBL] [Abstract][Full Text] [Related]
13. Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration.
Jolly SS; James S; Džavík V; Cairns JA; Mahmoud KD; Zijlstra F; Yusuf S; Olivecrona GK; Renlund H; Gao P; Lagerqvist B; Alazzoni A; Kedev S; Stankovic G; Meeks B; Frøbert O
Circulation; 2017 Jan; 135(2):143-152. PubMed ID: 27941066
[TBL] [Abstract][Full Text] [Related]
14. Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events.
Maret-Ouda J; Santoni G; Xie S; Rosengren A; Lagergren J
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1121-1128. PubMed ID: 34241731
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
[TBL] [Abstract][Full Text] [Related]
16. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
[TBL] [Abstract][Full Text] [Related]
17. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.
Bhurke SM; Martin BC; Li C; Franks AM; Bursac Z; Said Q
Pharmacotherapy; 2012 Sep; 32(9):809-18. PubMed ID: 22744772
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.
Lin CF; Shen LJ; Wu FL; Bai CH; Gau CS
Br J Clin Pharmacol; 2012 Nov; 74(5):824-34. PubMed ID: 22364155
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
[TBL] [Abstract][Full Text] [Related]
20. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
